Trial Outcomes & Findings for ZS Ph2/3 Dose-response Study in Japan (NCT NCT03127644)
NCT ID: NCT03127644
Last Updated: 2019-05-20
Results Overview
Blood samples for determination of potassium were collected pre-dose, and at 1, 2, and 4 hours post Dose 1 on Day 1. An additional sample was collected at 90 minutes post Dose 2 on Day 1 if i-STAT potassium values at the 4-hour post Dose 1 time point was ≥ 6.1 or \<4.0 mmol/L. On Day 2 samples were analysed pre-dose, and 1 and 4 hours post Dose 1. S-K levels were analysed at the Central Laboratory. Natural logarithm of S-K from 0 to 48 hours post dose are modelled by the random coefficients model including fixed effects of intercept, time, time x treatment and patient-level random effects for time and intercept. Exponential rate of change refers to the slope estimate from the random coefficients model.
COMPLETED
PHASE2/PHASE3
103 participants
From 0 to 48 hours.
2019-05-20
Participant Flow
Patients not receiving any therapy for hyperkalaemia and with 2 consecutive potassium values of ≥ 5.1 millimoles/litre (mmol/L) and ≤ 6.5 mmol/L (as measured by i-STAT, a portable blood analyser) were enrolled into 24 study sites in Japan from June 2017 to February 2018.
103 patients were randomised 1:1:1 to receive double-blind treatment of sodium zirconium cyclosilicate (ZS) 5 grams (g) three times daily (TID), ZS 10 g TID, or placebo TID for 48 hours.
Participant milestones
| Measure |
ZS 5 g TID
ZS suspension was administered 5 g orally TID for 48 hours.
|
ZS 10 g TID
ZS suspension was administered 10 g orally TID for 48 hours.
|
Placebo TID
Placebo suspension was administered orally TID for 48 hours.
|
|---|---|---|---|
|
Overall Study
STARTED
|
34
|
36
|
33
|
|
Overall Study
COMPLETED
|
34
|
36
|
31
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
2
|
Reasons for withdrawal
| Measure |
ZS 5 g TID
ZS suspension was administered 5 g orally TID for 48 hours.
|
ZS 10 g TID
ZS suspension was administered 10 g orally TID for 48 hours.
|
Placebo TID
Placebo suspension was administered orally TID for 48 hours.
|
|---|---|---|---|
|
Overall Study
Study-specific withdrawal criteria
|
0
|
0
|
2
|
Baseline Characteristics
ZS Ph2/3 Dose-response Study in Japan
Baseline characteristics by cohort
| Measure |
ZS 5 g TID
n=34 Participants
ZS suspension was administered 5 g orally TID for 48 hours.
|
ZS 10 g TID
n=36 Participants
ZS suspension was administered 10 g orally TID for 48 hours.
|
Placebo TID
n=33 Participants
Placebo suspension was administered orally TID for 48 hours.
|
Total
n=103 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Continuous
|
72.4 Years
STANDARD_DEVIATION 7.9 • n=99 Participants
|
71.1 Years
STANDARD_DEVIATION 7.6 • n=107 Participants
|
76.1 Years
STANDARD_DEVIATION 6.8 • n=206 Participants
|
73.2 Years
STANDARD_DEVIATION 7.7 • n=7 Participants
|
|
Age, Customized
<55 years
|
0 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
1 Participants
n=7 Participants
|
|
Age, Customized
55 to 64 years
|
7 Participants
n=99 Participants
|
4 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
12 Participants
n=7 Participants
|
|
Age, Customized
≥65 years
|
27 Participants
n=99 Participants
|
31 Participants
n=107 Participants
|
32 Participants
n=206 Participants
|
90 Participants
n=7 Participants
|
|
Sex: Female, Male
Female
|
8 Participants
n=99 Participants
|
8 Participants
n=107 Participants
|
10 Participants
n=206 Participants
|
26 Participants
n=7 Participants
|
|
Sex: Female, Male
Male
|
26 Participants
n=99 Participants
|
28 Participants
n=107 Participants
|
23 Participants
n=206 Participants
|
77 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
34 Participants
n=99 Participants
|
36 Participants
n=107 Participants
|
33 Participants
n=206 Participants
|
103 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Asian
|
34 Participants
n=99 Participants
|
36 Participants
n=107 Participants
|
33 Participants
n=206 Participants
|
103 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Race (NIH/OMB)
White
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
PRIMARY outcome
Timeframe: From 0 to 48 hours.Population: The full analysis set included all patients randomised in the study.
Blood samples for determination of potassium were collected pre-dose, and at 1, 2, and 4 hours post Dose 1 on Day 1. An additional sample was collected at 90 minutes post Dose 2 on Day 1 if i-STAT potassium values at the 4-hour post Dose 1 time point was ≥ 6.1 or \<4.0 mmol/L. On Day 2 samples were analysed pre-dose, and 1 and 4 hours post Dose 1. S-K levels were analysed at the Central Laboratory. Natural logarithm of S-K from 0 to 48 hours post dose are modelled by the random coefficients model including fixed effects of intercept, time, time x treatment and patient-level random effects for time and intercept. Exponential rate of change refers to the slope estimate from the random coefficients model.
Outcome measures
| Measure |
ZS 5 g TID
n=34 Participants
ZS suspension was administered 5 g orally TID for 48 hours.
|
ZS 10 g TID
n=36 Participants
ZS suspension was administered 10 g orally TID for 48 hours.
|
Placebo TID
n=33 Participants
Placebo suspension was administered orally TID for 48 hours.
|
|---|---|---|---|
|
Exponential Rate of Change in Serum Potassium (S-K) Values During the Initial 48 Hours of Study Drug Treatment
|
-0.00273 log (mmol/L) / hour
Standard Error 0.000276
|
-0.00508 log (mmol/L) / hour
Standard Error 0.000269
|
-0.00012 log (mmol/L) / hour
Standard Error 0.000288
|
SECONDARY outcome
Timeframe: At 48 hours.Population: The full analysis set included all patients randomised in the study.
The percentage of patients who achieved normokalaemia (normalisation of S-K values to between 3.5 mmol/L and 5.0 mmol/L, inclusive) at 48 hours after start of dosing was determined. Patients with missing S-K values at 48 hours were regarded as not normokalaemic.
Outcome measures
| Measure |
ZS 5 g TID
n=34 Participants
ZS suspension was administered 5 g orally TID for 48 hours.
|
ZS 10 g TID
n=36 Participants
ZS suspension was administered 10 g orally TID for 48 hours.
|
Placebo TID
n=33 Participants
Placebo suspension was administered orally TID for 48 hours.
|
|---|---|---|---|
|
Percentage of Patients Who Achieved Normokalaemia at 48 Hours
|
85.3 Percentage of Patients
|
91.7 Percentage of Patients
|
15.2 Percentage of Patients
|
SECONDARY outcome
Timeframe: From 0 to 24 hours.Population: The full analysis set included all patients randomised in the study.
Blood samples for determination of potassium were collected pre-dose, and at 1, 2, and 4 hours post Dose 1 on Day 1. An additional sample was collected at 90 minutes post Dose 2 on Day 1 if i-STAT potassium values at the 4-hour post Dose 1 time point was ≥ 6.1 or \<4.0 mmol/L. On Day 2 samples were analysed pre-dose, and 1 and 4 hours post Dose 1. S-K levels were analysed at the Central Laboratory. Natural logarithm of S-K from 0 to 24 hours post dose are modelled by the random coefficients model including fixed effects of intercept, time, time x treatment and patient-level random effects for time and intercept. Exponential rate of change refers to the slope estimate from the random coefficients model.
Outcome measures
| Measure |
ZS 5 g TID
n=34 Participants
ZS suspension was administered 5 g orally TID for 48 hours.
|
ZS 10 g TID
n=36 Participants
ZS suspension was administered 10 g orally TID for 48 hours.
|
Placebo TID
n=33 Participants
Placebo suspension was administered orally TID for 48 hours.
|
|---|---|---|---|
|
Exponential Rate of Change in S-K Values During the Initial 24 Hours of Study Drug Treatment
|
-0.00234 log (mmol/L) / hour
Standard Error 0.000468
|
-0.00403 log (mmol/L) / hour
Standard Error 0.000457
|
-0.00002 log (mmol/L) / hour
Standard Error 0.000489
|
SECONDARY outcome
Timeframe: At 24 hours.Population: The full analysis set included all patients randomised in the study.
The percentage of patients who achieved normokalaemia (normalisation of S-K values to between 3.5 mmol/L and 5.0 mmol/L, inclusive) at 24 hours after start of dosing was determined. Patients with missing S-K values at 24 hours were regarded as not normokalaemic.
Outcome measures
| Measure |
ZS 5 g TID
n=34 Participants
ZS suspension was administered 5 g orally TID for 48 hours.
|
ZS 10 g TID
n=36 Participants
ZS suspension was administered 10 g orally TID for 48 hours.
|
Placebo TID
n=33 Participants
Placebo suspension was administered orally TID for 48 hours.
|
|---|---|---|---|
|
Percentage of Patients Who Achieved Normokalaemia at 24 Hours
|
35.3 Percentage of Patients
|
83.3 Percentage of Patients
|
27.3 Percentage of Patients
|
SECONDARY outcome
Timeframe: From baseline to end of study (9 days).Population: The full analysis set included all patients randomised in the study.
The percentage of patients who achieved normokalaemia (normalisation of S-K values to between 3.5 mmol/L and 5.0 mmol/L, inclusive) at each each scheduled potassium assessment time point after the start of dosing was determined. Patients with missing S-K values were regarded as not normokalaemic.
Outcome measures
| Measure |
ZS 5 g TID
n=34 Participants
ZS suspension was administered 5 g orally TID for 48 hours.
|
ZS 10 g TID
n=36 Participants
ZS suspension was administered 10 g orally TID for 48 hours.
|
Placebo TID
n=33 Participants
Placebo suspension was administered orally TID for 48 hours.
|
|---|---|---|---|
|
Percentage of Patients Who Achieved Normokalaemia at Each Scheduled Potassium Assessment Time Point
Baseline
|
2.9 Percentage of Patients
|
5.6 Percentage of Patients
|
0.0 Percentage of Patients
|
|
Percentage of Patients Who Achieved Normokalaemia at Each Scheduled Potassium Assessment Time Point
1 hour after first dose
|
29.4 Percentage of Patients
|
47.2 Percentage of Patients
|
21.2 Percentage of Patients
|
|
Percentage of Patients Who Achieved Normokalaemia at Each Scheduled Potassium Assessment Time Point
2 hours after first dose
|
41.2 Percentage of Patients
|
58.3 Percentage of Patients
|
42.4 Percentage of Patients
|
|
Percentage of Patients Who Achieved Normokalaemia at Each Scheduled Potassium Assessment Time Point
4 hours after first dose
|
44.1 Percentage of Patients
|
63.9 Percentage of Patients
|
42.4 Percentage of Patients
|
|
Percentage of Patients Who Achieved Normokalaemia at Each Scheduled Potassium Assessment Time Point
24 hours after first dose
|
35.3 Percentage of Patients
|
83.3 Percentage of Patients
|
27.3 Percentage of Patients
|
|
Percentage of Patients Who Achieved Normokalaemia at Each Scheduled Potassium Assessment Time Point
25 hours after first dose
|
73.5 Percentage of Patients
|
97.2 Percentage of Patients
|
18.2 Percentage of Patients
|
|
Percentage of Patients Who Achieved Normokalaemia at Each Scheduled Potassium Assessment Time Point
28 hours after first dose
|
67.6 Percentage of Patients
|
97.2 Percentage of Patients
|
36.4 Percentage of Patients
|
|
Percentage of Patients Who Achieved Normokalaemia at Each Scheduled Potassium Assessment Time Point
48 hours after first dose
|
85.3 Percentage of Patients
|
91.7 Percentage of Patients
|
15.2 Percentage of Patients
|
|
Percentage of Patients Who Achieved Normokalaemia at Each Scheduled Potassium Assessment Time Point
End of study (Last dose + 7 days)
|
55.9 Percentage of Patients
|
61.1 Percentage of Patients
|
27.3 Percentage of Patients
|
SECONDARY outcome
Timeframe: From baseline to end of study (9 days).Population: The full analysis set included all patients randomised in the study.
Blood samples for determination of potassium were collected pre-dose, and at 1, 2, and 4 hours post Dose 1 on Day 1. An additional sample was collected at 90 minutes post Dose 2 on Day 1 if i-STAT potassium values at the 4-hour post Dose 1 time point was ≥ 6.1 or \<4.0 mmol/L. On Day 2 samples were analysed pre-dose, and 1 and 4 hours post Dose 1. S-K levels were analysed locally using i-STAT devices, and at the Central Laboratory. S-K values measured at each time point and end of study visit were recorded and mean change from baseline is displayed.
Outcome measures
| Measure |
ZS 5 g TID
n=34 Participants
ZS suspension was administered 5 g orally TID for 48 hours.
|
ZS 10 g TID
n=36 Participants
ZS suspension was administered 10 g orally TID for 48 hours.
|
Placebo TID
n=33 Participants
Placebo suspension was administered orally TID for 48 hours.
|
|---|---|---|---|
|
Mean Change From Baseline in S-K Values at All Measured Time Intervals
1 hour after first dose
|
-0.20 mmol/L
Standard Deviation 0.34
|
-0.37 mmol/L
Standard Deviation 0.35
|
-0.13 mmol/L
Standard Deviation 0.32
|
|
Mean Change From Baseline in S-K Values at All Measured Time Intervals
2 hours after first dose
|
-0.41 mmol/L
Standard Deviation 0.28
|
-0.50 mmol/L
Standard Deviation 0.40
|
-0.33 mmol/L
Standard Deviation 0.30
|
|
Mean Change From Baseline in S-K Values at All Measured Time Intervals
4 hours after first dose
|
-0.40 mmol/L
Standard Deviation 0.32
|
-0.53 mmol/L
Standard Deviation 0.36
|
-0.43 mmol/L
Standard Deviation 0.31
|
|
Mean Change From Baseline in S-K Values at All Measured Time Intervals
24 hours after first dose
|
-0.51 mmol/L
Standard Deviation 0.30
|
-0.69 mmol/L
Standard Deviation 0.38
|
-0.22 mmol/L
Standard Deviation 0.35
|
|
Mean Change From Baseline in S-K Values at All Measured Time Intervals
25 hours after first dose
|
-0.74 mmol/L
Standard Deviation 0.31
|
-1.00 mmol/L
Standard Deviation 0.45
|
-0.27 mmol/L
Standard Deviation 0.31
|
|
Mean Change From Baseline in S-K Values at All Measured Time Intervals
28 hours after first dose
|
-0.72 mmol/L
Standard Deviation 0.35
|
-1.12 mmol/L
Standard Deviation 0.39
|
-0.41 mmol/L
Standard Deviation 0.43
|
|
Mean Change From Baseline in S-K Values at All Measured Time Intervals
48 hours after first dose
|
-0.83 mmol/L
Standard Deviation 0.31
|
-1.30 mmol/L
Standard Deviation 0.48
|
-0.24 mmol/L
Standard Deviation 0.34
|
|
Mean Change From Baseline in S-K Values at All Measured Time Intervals
End of study (Last dose + 7 days)
|
-0.56 mmol/L
Standard Deviation 0.38
|
-0.66 mmol/L
Standard Deviation 0.52
|
-0.20 mmol/L
Standard Deviation 0.59
|
SECONDARY outcome
Timeframe: From baseline to end of study (9 days).Population: The full analysis set included all patients randomised in the study.
Blood samples for determination of potassium were collected pre-dose, and at 1, 2, and 4 hours post Dose 1 on Day 1. An additional sample was collected at 90 minutes post Dose 2 on Day 1 if i-STAT potassium values at the 4-hour post Dose 1 time point was ≥ 6.1 or \<4.0 mmol/L. On Day 2 samples were analysed pre-dose, and 1 and 4 hours post Dose 1. S-K levels were analysed locally using i-STAT devices, and at the Central Laboratory. S-K values measured at each time point and end of study visit were recorded and mean percent change from baseline is displayed.
Outcome measures
| Measure |
ZS 5 g TID
n=34 Participants
ZS suspension was administered 5 g orally TID for 48 hours.
|
ZS 10 g TID
n=36 Participants
ZS suspension was administered 10 g orally TID for 48 hours.
|
Placebo TID
n=33 Participants
Placebo suspension was administered orally TID for 48 hours.
|
|---|---|---|---|
|
Mean Percent Change From Baseline in S-K Values at All Measured Time Intervals
1 hour after first dose
|
-3.61 Percent change
Standard Deviation 6.28
|
-6.72 Percent change
Standard Deviation 6.29
|
-2.32 Percent change
Standard Deviation 5.60
|
|
Mean Percent Change From Baseline in S-K Values at All Measured Time Intervals
2 hours after first dose
|
-7.46 Percent change
Standard Deviation 5.04
|
-9.07 Percent change
Standard Deviation 6.88
|
-6.06 Percent change
Standard Deviation 5.40
|
|
Mean Percent Change From Baseline in S-K Values at All Measured Time Intervals
4 hours after first dose
|
-7.08 Percent change
Standard Deviation 5.65
|
-9.70 Percent change
Standard Deviation 6.53
|
-7.77 Percent change
Standard Deviation 5.62
|
|
Mean Percent Change From Baseline in S-K Values at All Measured Time Intervals
24 hours after first dose
|
-8.98 Percent change
Standard Deviation 5.33
|
-12.51 Percent change
Standard Deviation 6.30
|
-3.81 Percent change
Standard Deviation 6.24
|
|
Mean Percent Change From Baseline in S-K Values at All Measured Time Intervals
25 hours after first dose
|
-13.20 Percent change
Standard Deviation 5.42
|
-18.06 Percent change
Standard Deviation 7.05
|
-4.77 Percent change
Standard Deviation 5.66
|
|
Mean Percent Change From Baseline in S-K Values at All Measured Time Intervals
28 hours after first dose
|
-12.90 Percent change
Standard Deviation 6.10
|
-20.47 Percent change
Standard Deviation 6.38
|
-7.21 Percent change
Standard Deviation 7.61
|
|
Mean Percent Change From Baseline in S-K Values at All Measured Time Intervals
48 hours after first dose
|
-14.81 Percent change
Standard Deviation 5.08
|
-23.64 Percent change
Standard Deviation 8.27
|
-4.06 Percent change
Standard Deviation 5.93
|
|
Mean Percent Change From Baseline in S-K Values at All Measured Time Intervals
End of study (Last dose + 7 days)
|
-9.85 Percent change
Standard Deviation 6.51
|
-11.89 Percent change
Standard Deviation 9.07
|
-3.15 Percent change
Standard Deviation 9.99
|
SECONDARY outcome
Timeframe: From 0 to 48 hours.Population: The full analysis set included all patients randomised in the study.
The distribution of time to normalisation of S-K values (defined as S-K values between 3.5 mmol/L and 5.0 mmol/L, inclusive) was measured. A patient who reached at least one S-K within normal range was counted as an event regardless of S-K value after that time point. Patients who did not achieve normokalaemia within 48 hours were censored.
Outcome measures
| Measure |
ZS 5 g TID
n=34 Participants
ZS suspension was administered 5 g orally TID for 48 hours.
|
ZS 10 g TID
n=36 Participants
ZS suspension was administered 10 g orally TID for 48 hours.
|
Placebo TID
n=33 Participants
Placebo suspension was administered orally TID for 48 hours.
|
|---|---|---|---|
|
Time to Normalisation in S-K Values
|
3.883 Hours
Interval 1.767 to 23.083
|
1.758 Hours
Interval 1.0 to 3.967
|
3.867 Hours
Interval 1.917 to
Upper limit not reached.
|
SECONDARY outcome
Timeframe: From 0 to 48 hours.Population: The full analysis set included all patients randomised in the study.
The median time (hours) for S-K values to decrease by 0.5 mmol/L was measured.
Outcome measures
| Measure |
ZS 5 g TID
n=34 Participants
ZS suspension was administered 5 g orally TID for 48 hours.
|
ZS 10 g TID
n=36 Participants
ZS suspension was administered 10 g orally TID for 48 hours.
|
Placebo TID
n=33 Participants
Placebo suspension was administered orally TID for 48 hours.
|
|---|---|---|---|
|
Time to a Decrease in S-K Levels of 0.5 mmol/L
|
3.883 Hours
Interval 1.933 to 19.767
|
2.892 Hours
Interval 1.083 to 4.1
|
4.050 Hours
Interval 1.983 to 23.667
|
Adverse Events
ZS 5 g TID
ZS 10 g TID
Placebo TID
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
ZS 5 g TID
n=34 participants at risk
ZS suspension was administered 5 g orally TID for 48 hours.
|
ZS 10 g TID
n=36 participants at risk
ZS suspension was administered 10 g orally TID for 48 hours.
|
Placebo TID
n=33 participants at risk
Placebo suspension was administered orally TID for 48 hours.
|
|---|---|---|---|
|
Infections and infestations
Respiratory tract infection
|
0.00%
0/34 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
|
0.00%
0/36 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
|
3.0%
1/33 • Number of events 1 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
|
|
Infections and infestations
Viral upper respiratory tract infection
|
2.9%
1/34 • Number of events 1 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
|
0.00%
0/36 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
|
0.00%
0/33 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
|
|
Blood and lymphatic system disorders
Nephrogenic anaemia
|
2.9%
1/34 • Number of events 1 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
|
0.00%
0/36 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
|
0.00%
0/33 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
0.00%
0/34 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
|
2.8%
1/36 • Number of events 1 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
|
0.00%
0/33 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
|
|
Nervous system disorders
Tension headache
|
0.00%
0/34 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
|
2.8%
1/36 • Number of events 1 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
|
0.00%
0/33 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
|
|
Nervous system disorders
Tremor
|
0.00%
0/34 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
|
2.8%
1/36 • Number of events 5 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
|
0.00%
0/33 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
|
|
Cardiac disorders
Ventricular extrasystoles
|
0.00%
0/34 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
|
2.8%
1/36 • Number of events 1 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
|
0.00%
0/33 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
|
|
Gastrointestinal disorders
Constipation
|
2.9%
1/34 • Number of events 1 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
|
0.00%
0/36 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
|
0.00%
0/33 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
|
|
Skin and subcutaneous tissue disorders
Erythema
|
0.00%
0/34 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
|
2.8%
1/36 • Number of events 1 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
|
0.00%
0/33 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
|
|
General disorders
Thirst
|
2.9%
1/34 • Number of events 1 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
|
0.00%
0/36 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
|
0.00%
0/33 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place